Clinical Trials

Carcinoma, Non-Small-Cell Lung

NCT00596648 2026-01-13

A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Completed

92 enrolled 14 charts

674 enrolled 21 charts 1 FDA

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02296125 2026-01-09

FLAURA

Phase 3 Completed

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

NCT07271446 2025-12-09

An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer

8 enrolled

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT04172779 2025-11-20

ECHO-B

60 enrolled

Carcinoma, Hepatocellular, Liver Cirrhosis

NCT01221077 2025-11-18

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

88 enrolled

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT00600496 2025-11-13

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

140 enrolled

BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT00977470 2025-10-15

Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations

Phase 2 Active not recruiting

76 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT00885066 2025-09-30

Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer

30 enrolled

Phase 1 Active not recruiting

Pancreatic Neoplasms

NCT03653546 2025-09-10

BM

Phase 2/3 Completed

492 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Respiratory Tract Diseases

NCT02099058 2025-08-14

A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

237 enrolled

Neoplasms

NCT05442060 2025-08-03

EGFR

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04341181 2025-07-25

ProTarget

300 enrolled

Neoplasms

NCT06161558 2025-07-16

Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors

Phase 1 Withdrawn

Neoplasms

NCT06997068 2025-07-14

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population

Phase 2 Active not recruiting

25 enrolled

Head & Neck

Mouth Neoplasms

NCT00076310 2025-06-26

OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer

50 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT02991651 2025-05-14

Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC

Phase 1 Terminated

12 enrolled

Carcinoma, Non-Small-Cell Lung

NCT00405405 2025-05-06

Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer

13 enrolled

DermatologicHead & Neck

Head and Neck Neoplasms, Melanoma, Parotid Neoplasms, Thyroid Neoplasms

NCT00954525 2025-05-02

Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer

14 enrolled

Pancreatic Neoplasms

NCT00640978 2025-05-01

Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer

Phase 2 Terminated

16 enrolled 4 charts

Neoplasm Metastasis, Pancreatic Neoplasms

NCT00942734 2025-05-01

Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma

49 enrolled 5 charts

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT00983307 2025-04-30

A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer

17 enrolled 9 charts

DermatologicGastrointestinal

Carcinoma, Non-Small-Cell Lung

NCT06483555 2025-04-16

PANGEA

Phase 1/2 Recruiting

104 enrolled

Pancreatic Neoplasms, Neoplasms, Basal Cell

NCT05834348 2025-03-30

DELINOR

Completed

5,279 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT00503971 2025-03-07

Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.

Phase 1/2 Terminated

33 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung

NCT00446225 2025-03-05

EURTAC

Phase 3 Completed

174 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02535338 2025-03-03

Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer

Phase 1/2 Completed

11 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT02424617 2025-02-26

A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer

Phase 1/2 Completed

40 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT01130519 2025-02-21

A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer

83 enrolled 17 charts

Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, Kidney Neoplasms

NCT00708448 2025-02-13

Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients

26 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT06071013 2025-01-23

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Phase 1/2 Recruiting

20 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01032070 2024-12-12

PETEY

Phase 2 Terminated

25 enrolled 23 charts

Familial ependymoma, Ependymoma, Recurrence

NCT02588261 2024-12-10

SOLAR

Phase 3 Terminated

530 enrolled 25 charts

Carcinoma, Non-Small-Cell Lung

NCT01247922 2024-12-06

Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205

Phase 2 Terminated

4 enrolled 9 charts

Familial ependymoma, Ependymoma

NCT02495233 2024-11-27

A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)

Phase 1/2 Terminated

10 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung

NCT01010945 2024-11-21

Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer

19 enrolled

Adenocarcinoma

NCT00739453 2024-11-20

A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)

GastrointestinalGenitourinaryThoracic

95 enrolled

Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT02057380 2024-11-20

A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial

13 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT04322890 2024-10-22

PIKACHU

6,000 enrolled